Resources for You
Vagifem (Estradiol) Vaginal Tablet
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – April 2012
- Known anaphylactic reaction or angioedema to Vagifem
- Known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders
WARNINGS AND PRECAUTIONS
- Exogenous estrogens may exacerbate symptoms of angioedema in women with hereditary angioedema.